MaxCyte, Inc. Morgan Stanley Healthcare Conference Participation

TIDMMXCT

MaxCyte, Inc.

08 September 2022

MaxCyte to Participate in Morgan Stanley 20(th) Annual Global Healthcare Conference

Rockville, MD, September 8, 2022 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell -engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced Company management will present at the Morgan Stanley 20(th) Annual Global Healthcare Conference on Tuesday, September 13(th) at 4:40 p.m. Eastern Time.

A live and archived webcast of the event will be available on the "Events" section of the MaxCyte investor relations website at https://investors.maxcyte.com/.

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation(R) platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT(TM) platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx(TM), STx(TM), GTx(TM), and VLx(TM); a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

MaxCyte Contacts:

 
 US IR Adviser                                    +1 415-937-5400 
  Gilmartin Group                                  ir@maxcyte.com 
  David Deuchler, CFA 
 Nominated Adviser and Joint Corporate Broker 
  Panmure Gordon 
  Emma Earl / Freddy Crossley 
  Corporate Broking 
  Rupert Dearden                                  +44 (0)20 7886 2500 
                                                  +44 (0)203 709 5700 
   UK IR Adviser                                   maxcyte@consilium-comms.com 
   Consilium Strategic Communications 
   Mary-Jane Elliott 
   Chris Welsh

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRASSIFIWEESEFU

(END) Dow Jones Newswires

September 08, 2022 02:01 ET (06:01 GMT)

Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024